OraVital’s 2017 KOL Access Webinar Series

Dr. Bradley Bale & Dr. Amy Doneen Kick-Off

OraVital’s 2017 KOL Access Webinar Series

The Presenters Will Review the Findings of Their British Medical Journal Paper That Shows High Risk Periodontal Pathogens

are a Contributory Cause of Arterial Disease

Toronto, CA – January 10, 2017 – OraVital Inc., The Oral Infection Experts™, will be kicking off its 2017 KOL Access Webinar Series, with two of the leading pioneers of the oral-systemic health movement; Dr. Bradley Bale and Dr. Amy Doneen, who are the authors of the best-selling book, “Beat the Heart Attack Gene”

Long time advocates of the critical role that dental professionals play in the prevention of heart attacks and strokes, Drs. Bale and Doneen recently co-authored an article with Dr. David Vigerust that will be published in print in the prestigious Postgraduate Medical Journal and was published online ahead of print by the British Medical Journal (BMJ) entitled, “High-Risk Periodontal Pathogens Contribute to the Pathogenesis of Atherosclerosis.”

According to OraVital CEO, Dr. Jim Hyland, “This is a ground-breaking report that further validates the oral-systemic health link in general and more specifically, the perio-cardio link. The PGMJ /BMJ manuscript clearly states, ‘periodontal disease due to high risk pathogens is a cause of arterial disease.’ Now more than ever, dental clinicians can and should strengthen their commitment identifying and managing this form of periodontal disease.”  

-more-

Because of the complexity of the topic and because atherosclerosis is the largest cause of death and disability in North America, Drs. Bale and Doneen have been invited to present their findings in a two-part CE webinar. The schedule is as follows:

·       Thursday, 2/9/17 l 8:30 PM EST: “High-Risk Periodontal Pathogens Contribute to the Pathogenesis of Atherosclerosis.” l Presented by Bradley Field Bale, M.D. l 1 CEU

According to Dr. Bale, “Periodontal disease due to high risk pathogens must be considered a contributory cause of arterial disease.  Dr. Bale will present the science which supports this landmark statement.  Considering this knowledge, the dental community has a significant opportunity to favorably impact the number one cause of death and disability by effectively managing this type of periodontal disease.”

·       Thursday, 3/9/17 l 8:30 PM EST: “Integrating the Science of Oral/Systemic Health into Clinical Practice.” l Presented by Amy Doneen, DNP, ARNP l 1 CEU

“It is necessary to respect the clinical context for which the information outlined in the recent BMJ study can be applied to the clinical dental arena,” explained Dr. Doneen. “What’s more, lines of communication must be created between medicine and dentistry that can clearly articulate the importance of understanding the oral pathogen burden as it relates to the vascular health of the individual patient.”  

For more information on the 2017 KOL Access Webinar Series, sponsored by OraVital^® and how to register for each upcoming webinar, visit https://www.oravital.com/KOL2017. Dental industry thought leaders wishing to participate in future KOL Access Webinars are invited to send an abstract to Michael@Ventriello.com.

About Bradley Bale, MD:  Dr. Bale is an Adjunct Professor at Texas Tech Health Science Center, Medical Director of the Heart Health Program at Grace Clinic, Lubbock, Texas and Co-founder of The Bale/Doneen Method.  This precision healthcare system has been shown to halt, stabilize and regress arterial disease. 

-more-

About Amy L. Doneen, DNP, ARNP:  Dr. Doneen co-founded the Bale/Doneen Method, which ensures arterial wellness.  She is medical director of The Heart Attack & Stroke Prevention Center and adjunct professor at Texas Tech Health Sciences.  Dr. Doneen is a national thought-leader and co-author of the bestselling book, Beat the Heart Attack Gene.  

About OraVital Inc.

Headquartered in Toronto, Canada, OraVital Inc., is the developer of the comprehensive OraVital^® System, which provides the most accurate diagnosis and effective treatment of the oral infections that cause periodontal disease, halitosis, peri-implantitis and caries. Consisting of a proprietary protocol of advanced microbiology tests BioFilmDNA™ and BioFilmGS™ (Gram stain), combined with a personalized regimen of prescribed antibiotic/antifungal and antimicrobial rinses, the OraVital^® System controls 90% of periodontal disease, halitosis, peri-implantitis and caries in just 4 weeks when used as directed. For more information, visit www.OraVital.com.

# # #